Kevin M. Slawin

Medicine · Health Sciences

63h-index15.1kcitations259works0.02yr avg
OpenAlex↗Google Scholar↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Prostate Cancer Diagnosis and Treatment(129), Prostate Cancer Treatment and Research(127), Immunotherapy and Immune Responses(39), Urologic and reproductive health conditions(37), Urinary Bladder and Prostate Research(28)

Publications258 total

Supplementary Figures 1-8 from Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation
2023Open Access
Supplementary Methods from Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation
2023Open Access
Data from Versatile Prostate Cancer Treatment with Inducible Caspase and Interleukin-12
2023Open Access
Data from Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation
2023Open Access
Supplementary Figures 1-8 from Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation
2023Open Access
Supplementary Figures 1-4 from Versatile Prostate Cancer Treatment with Inducible Caspase and Interleukin-12
2023Open Access
Supplementary Methods from Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation
2023Open Access
Supplementary Figures 1-4 from Versatile Prostate Cancer Treatment with Inducible Caspase and Interleukin-12
2023Open Access
Data from Enhanced Activation of Human Dendritic Cells by Inducible CD40 and Toll-like Receptor-4 Ligation
2023Open Access
Data from Versatile Prostate Cancer Treatment with Inducible Caspase and Interleukin-12
2023Open Access
Constitutively active MyD88/CD40 costimulation enhances expansion and efficacy of chimeric antigen receptor T cells targeting hematological malignancies
Leukemia·2019· 78 citedOpen Access
Two-Dimensional Regulation of CAR-T Cell Therapy with Orthogonal Switches
Molecular Therapy — Oncolytics·2018· 83 citedOpen Access
A Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Utility of Tacrolimus (FK506) for the Prevention of Erectile Dysfunction Following Bilateral Nerve-Sparing Radical Prostatectomy
The Journal of Sexual Medicine·2018· 22 cited
Dual-Switch CAR-T Cells: Orthogonal Molecular Switches to Control Activation and Elimination of CAR-T Cells to Target CD123+ Cancer
Blood·2017
MyD88/CD40 Enhanced CD19-Specific CAR-T Cells Maintain Therapeutic Efficacy Following Resolution of Cytokine-Related Toxicity Using Inducible Caspase-9
Blood·2017
Regulated Expansion and Survival of Chimeric Antigen Receptor-Modified T Cells Using Small Molecule-Dependent Inducible MyD88/CD40
Molecular Therapy·2017· 103 citedOpen Access
Abstract 3745: Dual-switch TCR: A two-ligand system to control PRAME TCR-modified T cell proliferation and death using inducible MyD88/CD40 and caspase-9
Cancer Research·2017
Phase I trial of antigen-targeted autologous dendritic cell-based vaccine with in vivo activation of inducible CD40 for advanced prostate cancer
Cancer Immunology Immunotherapy·2017· 33 citedOpen Access
Phase 2 Study of <sup>99m</sup>Tc-Trofolastat SPECT/CT to Identify and Localize Prostate Cancer in Intermediate- and High-Risk Patients Undergoing Radical Prostatectomy and Extended Pelvic LN Dissection
Journal of Nuclear Medicine·2017· 74 citedOpen Access
Inducible MyD88/CD40 (iMC) Enhances Proliferation and Survival of Tumor-Specific TCR-Modified T Cells and Improves Anti-Tumor Efficacy in Myeloma
Blood·2016· 4 cited
page 1 of 13Next →

Frequent Co-authors

Thomas M. Wheeler(25), Peter T. Scardino(20), Shahrokh F. Shariat(18), Michael W. Kattan(13), Makoto Ohori(10), Claus G. Roehrborn(8), Alan W. Partin(6), William J. Catàlona(6), James A. Eastham(6), Norio Maru(6), Leonard S. Marks(5), Ben Andrews(5), Brian J. Miles(5), Dov Kadmon(5), Robert C. Flanigan(4), Patrick C. Walsh(4), Gail H. Gasior(4), Kathleen G Loveland(4), Paula C. Southwick(4), Hideshige Koh(4)